Bivamelagon clinical trials
Also written LB54640.
How each study uses bivamelagon is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the bivamelagon studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
3 studies that test it; most in 2023 (1)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 3
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses bivamelagon is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)Enrolling by invitationPhase 2Rhythm Pharmaceuticals, Inc.NCT07156578Written as Bivamelagon
- A Phase 2 Study to Assess Efficacy and Safety of LB54640 in Patients With Genetic ObesityNot yet recruitingPhase 2LG ChemNCT06041841Written as LB54640
- A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic ObesityCompletedPhase 2Rhythm Pharmaceuticals, Inc.NCT06046443Written as Bivamelagon
Codes
What other systems call bivamelagon · ClinicalTrials.gg INT017396
- UNII (FDA) NO1Y8WRA8NBIVAMELAGONConfirmed FDA, Wikidata
- Wikidata Q123844739bivamelagonConfirmed FDA, Wikidata
- NCI Thesaurus C203203BivamelagonOne source FDA
- DrugBank DB18331One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | NO1Y8WRA8N | BIVAMELAGON | Confirmed FDA, Wikidata |
| Wikidata | Q123844739 | bivamelagon | Confirmed FDA, Wikidata |
| NCI Thesaurus | C203203 | Bivamelagon | One source FDA |
| DrugBank | DB18331 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.